(Q33848566)

29 July 2017

title

Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer (English)

1 reference

29 July 2017

11

Loïc Campion

0 references

Christian Carrie

object named as

Christian Carrie

8

0 references

Erick Gamelin

15

object named as

Erick Gamelin

1 reference

29 July 2017

Michèle Boisdron-Celle

12

object named as

Michèle Boisdron-Celle

1 reference

29 July 2017

9

1 reference

29 July 2017

Patrice Cellier

1

1 reference

29 July 2017

Bernard Leduc

2

1 reference

29 July 2017

Laurent Martin

3

1 reference

29 July 2017

Brigitte Vié

4

1 reference

29 July 2017

Christian Chevelle

5

1 reference

29 July 2017

Véronique Vendrely

6

1 reference

29 July 2017

Augustin Salemkour

7

1 reference

29 July 2017

Pascal Burtin

10

1 reference

29 July 2017

Alain Morel

13

1 reference

29 July 2017

Virginie Berger

14

1 reference

29 July 2017

language of work or name

English

0 references

publication date

16 March 2011

1 reference

29 July 2017

1 reference

29 July 2017

volume

11

1 reference

29 July 2017

page(s)

98

1 reference

Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: a phase II study

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Recent advances in the treatment of localized rectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Optimal methods for staging rectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Chemotherapy with preoperative radiotherapy in rectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Can histopathologic assessment of circumferential margin after preoperative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for 3-year disease-free survival?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Preoperative versus postoperative chemoradiotherapy for rectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Preoperative uracil, tegafur, and concomitant radiotherapy in operable rectal cancer: a phase II multicenter study with 3 years' follow-Up

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Preoperative infusional chemoradiation therapy for Stage T3 rectal cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Reporting results of cancer treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Optimal two-stage designs for phase II clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-98

Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-98

Pre-operative chemoradiotherapy with oral tegafur-uracil and leucovorin for rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-98

Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-98

Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-98

Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-98

An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-98

Comparison of 5-fluorouracil/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-98

Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-98

Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2407-11-98

Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3070684

Phase I study of preoperative oral uracil and tegafur plus leucovorin and radiation therapy in rectal cancer

29 October 2018

1 reference

12 December 2020

Preoperative radiochemotherapy in rectal cancer: long-term results of a phase II trial

1 reference

12 December 2020

Fluoropyrimidine-Radiation Interactions in Cells and Tumors

1 reference

12 December 2020

Tumor downstaging and sphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience

1 reference

12 December 2020

Preoperative chemoradiotherapy for rectal cancer: randomized trial comparing oral uracil and tegafur and oral leucovorin vs. intravenous 5-fluorouracil and leucovorin

1 reference

12 December 2020

Sphincter preservation with preoperative radiation therapy and coloanal anastomosis

1 reference

12 December 2020

A phase II study of oral UFT and leucovorin concurrently with pelvic irradiation as neoadjuvant chemoradiation for rectal cancer

1 reference

12 December 2020

Risk factors for anastomotic leakage after preoperative chemoradiation therapy and low anterior resection with total mesorectal excision for locally advanced rectal cancer

1 reference

12 December 2020

Patterns of residual disease after preoperative chemoradiation in ultrasound T3 rectal carcinoma

1 reference

12 December 2020

Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance

1 reference

12 December 2020

[Scoring system of late effects of radiations on normal tissues: the SOMA-LENT scale]

1 reference

12 December 2020

Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144

1 reference

12 December 2020

Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation

1 reference

12 December 2020

Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosa

1 reference

12 December 2020

Phase II study of radiochemotherapy with UFT and low-dose oral leucovorin in patients with unresectable rectal cancer

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2407-11-98

1 reference

Dimensions Publication ID

29 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2407-11-98

9 September 2019

1 reference

29 July 2017

1 reference